Tag: file

BOCA RATON, FL, June 12, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today it will host a live Twitter Spaces event on Monday, June 16, 2025 at 1:00 PM ET to walk investors through the company’s recent S-1 filings, its newly announced $5 billion Equity Line of Credit (ELOC), and broader public market capital strategy.

CALGARY, ALBERTA, June 12, 2025 (GLOBE NEWSWIRE) -- Marksmen Energy Inc. ("Marksmen" or the "Company") is providing this update further to its news releases dated May 15, 2025 and May 29, 2025 with respect to the Alberta Securities Commission ("ASC"), having issued a management cease trade order ("MCTO") to Marksmen pursuant to its application under National Policy 12-203 Management Cease Trade Orders ("NP 12-203") in respect of the default regarding the delay of the filing of its annual financial statements, accompanying management’s discussion and analysis and related chief executive officer ("CEO") and chief financial officer ("CFO") certifications for the financial year ended December 31, 2024 (collectively, the "Annual Filings").

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025

Potential strategic alliance aims to transform residential real estate accessibility and transaction efficiency through exclusive integration of MiiX’s proprietary platform across La Rosa’s network

BOCA RATON, FL, June 12, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it has entered into a share purchase agreement (the “ELOC”) with RK Capital Management LLC (“RK Capital”).

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax¹